NKTX - Nkarta: Finally An Attractive Valuation
2024-05-25 02:20:02 ET
Summary
- Nkarta Inc. is using natural killer cells engineered with CARs and membrane-bound IL-15 to target autoimmune diseases and oncology.
- The company's off-the-shelf availability and superior safety profile make it an attractive option for patients, providers, and payers.
- Nkarta is targeting large markets, such as lupus nephritis and non-Hodgkin lymphoma, with the potential to produce blockbuster therapies.
I have a strong affinity for cell technology tickers attempting to push limits in order to provide cutting-edge therapies to the market to address some of the worst diseases known to man. It wasn’t that long ago the FDA approved the first CAR-T therapy, which was Novartis's ( NVS ) Kymriah (tisagenlecleucel) for acute lymphoblastic leukemia ( ALL ). Since then there have been a few more CAR-T therapies approved targeting lymphomas and myelomas. However, the development of cell therapies is just getting started as other firms attempt to employ other immune cells and improve upon the first-gen technology. Nkarta ( NKTX ) is one of these players, which uses natural killer (NK) cells engineered with chimeric antigen receptors ((CARs)) and membrane-bound IL-15 to take on both autoimmune diseases and oncology. Although the company’s pipeline is still young, the company’s technology could make it a game-changer in the cell therapy arena that is still largely up for grabs. NKTX has experienced a notable decline in its share price from its peak in March and is finally trading at an attractive valuation ahead of some potent catalysts and a financial runway projected to extend into 2027....
Nkarta: Finally An Attractive Valuation